StockData
CytoDyn Inc. logo

CytoDyn Inc. (CYDY) stock

CYDYOTCPharmaceutical PreparationsFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 14, 2026Score 4/30
$0.25+0.02 (+9.53%)

Close on Oct 19, 2026Market cap $345.56MP/E –Yield –

CytoDyn net income

Net income is the profit left for shareholders after every expense, interest and tax.

CytoDyn's net income for the twelve months ending Aug 31, 2026 was -$57.10M. For fiscal 2026 it was -$42.70M, down 1240.2% from the year before. The highest annual figure on record is $3.75M in fiscal 2025.

Annual net income

PeriodPeriod endValueChange
FY2026May 31, 2026-$42.70M-1240.2%
FY2025May 31, 2025$3.75M–
FY2024May 31, 2024-$49.84M–
FY2023May 31, 2023-$79.82M–
FY2022May 31, 2022-$210.82M–
FY2021May 31, 2021-$176.47M–
FY2020May 31, 2020-$139.94M–
FY2019May 31, 2019-$60.72M–
FY2018May 31, 2018-$50.15M–
FY2017May 31, 2017-$25.76M–
FY2016May 31, 2016-$25.70M–
FY2015May 31, 2015-$25.09M–
FY2014May 31, 2014-$12.43M–
FY2013May 31, 2013-$9.57M–
FY2012May 31, 2012-$7.47M–
FY2011May 31, 2011-$3.72M–
FY2010May 31, 2010-$3.36M–
FY2009May 31, 2009-$1.31M–
FY2008May 31, 2008-$1.19M–
FY2007May 31, 2007-$2.61M–
FY2006May 31, 2006-$2.05M–
FY2005May 31, 2005-$777.08K–

Quarterly net income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ3 2026Aug 31, 2026-$19.94M–
Q4 FY2026CQ2 2026May 31, 2026-$9.86M–
Q3 FY2026CQ1 2026Feb 28, 2026-$4.69M–
Q2 FY2026CQ4 2025Nov 30, 2025-$22.61M–
Q1 FY2026CQ3 2025Aug 31, 2025-$5.54M-128.8%
Q4 FY2025CQ2 2025May 31, 2025-$5.96M–
Q3 FY2025CQ1 2025Feb 28, 2025-$4.76M–
Q2 FY2025CQ4 2024Nov 30, 2024-$4.77M–
Q1 FY2025CQ3 2024Aug 31, 2024$19.23M–
Q4 FY2024CQ2 2024May 31, 2024-$16.79M–
Q3 FY2024CQ1 2024Feb 29, 2024-$11.92M–
Q2 FY2024CQ4 2023Nov 30, 2023-$9.56M–
Q1 FY2024CQ3 2023Aug 31, 2023-$11.57M–
Q2 FY2023CQ4 2022Nov 30, 2022-$26.50M–
Q1 FY2023CQ3 2022Aug 31, 2022-$20.99M–
Q4 FY2022CQ2 2022May 31, 2022-$84.12M–
Q3 FY2022CQ1 2022Feb 28, 2022-$41.29M–
Q2 FY2022CQ4 2021Nov 30, 2021-$40.08M–
Q1 FY2022CQ3 2021Aug 31, 2021-$45.34M–
Q4 FY2021CQ2 2021May 31, 2021-$70.07M–
Q3 FY2021CQ1 2021Feb 28, 2021-$37.58M–
Q2 FY2021CQ4 2020Nov 30, 2020-$37.98M–
Q1 FY2021CQ3 2020Aug 31, 2020-$30.83M–
Q4 FY2020CQ2 2020May 31, 2020-$73.14M–
Q3 FY2020CQ1 2020Feb 29, 2020-$35.77M–
Q2 FY2020CQ4 2019Nov 30, 2019-$14.86M–
Q1 FY2020CQ3 2019Aug 31, 2019-$16.16M–
Q4 FY2019CQ2 2019May 31, 2019-$19.43M–
Q3 FY2019CQ1 2019Feb 28, 2019-$12.57M–
Q2 FY2019CQ4 2018Nov 30, 2018-$14.31M–
Q1 FY2019CQ3 2018Aug 31, 2018-$14.41M–
Q4 FY2018CQ2 2018May 31, 2018-$9.62M–
Q3 FY2018CQ1 2018Feb 28, 2018-$17.95M–
Q2 FY2018CQ4 2017Nov 30, 2017-$10.95M–
Q1 FY2018CQ3 2017Aug 31, 2017-$11.63M–
Q4 FY2017CQ2 2017May 31, 2017-$6.83M–
Q3 FY2017CQ1 2017Feb 28, 2017-$8.11M–
Q2 FY2017CQ4 2016Nov 30, 2016-$5.26M–
Q1 FY2017CQ3 2016Aug 31, 2016-$8.90M–

More CytoDyn figures

See a number that looks wrong?